Literature DB >> 31028612

Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma.

Asmaa M Zahran1, Zeinab Albadry M Zahran2, Omnia El-Badawy3, Mona H Abdel-Rahim3, Wageeh A M Ali4, Amal Rayan5, Muhammad Abbas El-Masry6, Mohamed A A Abozaid6, Helal F Hetta7,8.   

Abstract

Toll-like receptors (TLRs) have a role in chronic inflammation. Still, little is known about the expression of TLRs in hepatocellular carcinoma (HCC). Herein, we tried to assess the prognostic value of TLR2 and TLR4 expression on circulating monocytes in HCC patients and correlate their levels with some clinical, laboratory data, and treatment outcomes. Forty patients with hepatic focal lesions diagnosed radiologically as HCC by triphasic multislice CT pelviabdominal and chest, and in some patients MRI diffusion and 38 age and sex matching healthy controls were enrolled in the study. Subjects were evaluated for liver functions, alpha-fetoprotein (AFP), imaging, response to different treatments, and overall survival. TLR2 and TLR4 expression by monocytes was detected by flow cytometry. The expression of both TLR2 and TLR4 on monocytes was significantly increased in HCC patients than the controls, in patients with more progressive HCC than those with lower progression and in patients with poor response to treatment than patients with better treatment response. Moreover, their levels showed positive correlations with ALT, AST, and AFP and inverse correlations with the overall survival of HCC patients. The results of the current study suggest that increased expression ofTLR2 and TLR4 on peripheral monocytes might reflect the development and progression of HCC and can be used to indicate poor prognosis. In addition, high expression of TLR2 correlated significantly with poor response to treatment, while high expression of both TLR2 and TLR4 were associated with poor survival. Our findings will help to design more studies on the role of TLRs in HCC pathogenesis and prognosis which may provide new therapeutic targets for HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; Inflammation; Overall survival; TLR; TLR2; TLR4

Mesh:

Substances:

Year:  2019        PMID: 31028612     DOI: 10.1007/s12026-019-09075-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  46 in total

Review 1.  TLR signaling.

Authors:  T Kawai; S Akira
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

Review 2.  Toll-like receptor signaling in the liver.

Authors:  Robert F Schwabe; Ekihiro Seki; David A Brenner
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

Review 3.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

4.  Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.

Authors:  Yi Zhe; Yan Li; Dan Liu; Dong-Ming Su; Jin-Gang Liu; Hang-Yu Li
Journal:  Tumour Biol       Date:  2016-08-04

5.  Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents.

Authors:  Le-Xing Yu; He-Xin Yan; Qiong Liu; Wen Yang; Hong-Ping Wu; Wei Dong; Liang Tang; Yan Lin; Ya-Qin He; Shan-Shan Zou; Chao Wang; Hui-Lu Zhang; Guang-Wen Cao; Meng-Chao Wu; Hong-Yang Wang
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.

Authors:  Jeremy B Swann; Matthew D Vesely; Anabel Silva; Janelle Sharkey; Shizuo Akira; Robert D Schreiber; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

8.  Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.

Authors:  Minesh Mehta; Helal F Hetta; Enass A Abdel-Hameed; Susan D Rouster; MdMonir Hossain; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Mohamed A El-Mokhtar; Sayed F Abdelwahab; Ahmed Medhat; Kenneth E Sherman; Mohamed Tarek M Shata
Journal:  Arch Virol       Date:  2016-08-20       Impact factor: 2.574

Review 9.  Toll-like receptors and adaptor molecules in liver disease: update.

Authors:  Ekihiro Seki; David A Brenner
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

10.  New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.

Authors:  Stephen L Chan; Frankie K F Mo; Philip J Johnson; Edwin P Hui; Brigette B Y Ma; Wing M Ho; Kwok C Lam; Anthony T C Chan; Tony S K Mok; Winnie Yeo
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

View more
  6 in total

1.  MD2 blockage prevents the migration and invasion of hepatocellular carcinoma cells via inhibition of the EGFR signaling pathway.

Authors:  Yajun Qi; Qilu Fang; Qinglin Li; Haiying Ding; Qi Shu; Yan Hu; Wenxiu Xin; Luo Fang
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Are Pattern Recognition Receptors Associated with Hepatocellular Carcinoma?

Authors:  Ramazan Dertli; Mehmet Asil; Murat Bıyık; Ahmet Karakarcayıldız; Muharrem Keskin; Yusuf Kayar; Müşerref Başdemirci; Hüseyin Ataseven
Journal:  Turk J Gastroenterol       Date:  2021-07       Impact factor: 1.852

3.  Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.

Authors:  Asmaa M Zahran; Helal F Hetta; Amal Rayan; Abeer Sharaf Eldin; Elham Ahmed Hassan; Hussein Fakhry; Ahmed Soliman; Omnia El-Badawy
Journal:  Cancer Immunol Immunother       Date:  2020-03-13       Impact factor: 6.968

4.  Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.

Authors:  Ming-Zhen Zhao; Yu Sun; Xiao-Feng Jiang; Li Liu; Li Liu; Li-Xin Sun
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 5.  Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries.

Authors:  Khaled Abouelezz; Dipen Khanapara; Gaber El-Saber Batiha; Esraa A Ahmed; Helal F Hetta
Journal:  Cancer Manag Res       Date:  2020-11-27       Impact factor: 3.989

6.  Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma-A Single-Center Study.

Authors:  Theodoros Androutsakos; Athanasios-Dimitrios Bakasis; Abraham Pouliakis; Maria Gazouli; Christos Vallilas; Gregorios Hatzis
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.